1
|
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PIM, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG. BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28:5265-73. [DOI: 10.1200/jco.2009.27.2294] [Citation(s) in RCA: 144] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival. Patients and Methods Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR). Results Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P < .00005), but not for ductal carcinoma in situ. Results in the BRCA1 group were worse compared to the BRCA2, the high-, and the moderate-risk groups, respectively, for mammography sensitivity (25.0% v 61.5%, 45.5%, 46.7%), tumor size at diagnosis ≤ 1 cm (21.4% v 61.5%, 40.9%, 63.6%), proportion of DCIS (6.5% v 18.8%, 14.8%, 31.3%) and interval cancers (32.3% v 6.3%, 3.7%, 6.3%), and age at diagnosis younger than 30 years (9.7% v 0%). Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n = 43). Conclusion Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.
Collapse
Affiliation(s)
- Adriana J. Rijnsburger
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Inge-Marie Obdeijn
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Reinoutje Kaas
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Madeleine M.A. Tilanus-Linthorst
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Carla Boetes
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Claudette E. Loo
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Martin N.J.M. Wasser
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Elisabeth Bergers
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Theo Kok
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Sara H. Muller
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Hans Peterse
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Rob A.E.M. Tollenaar
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Nicoline Hoogerbrugge
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Sybren Meijer
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Carina C.M. Bartels
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Caroline Seynaeve
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Maartje J. Hooning
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Mieke Kriege
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Paul I. M. Schmitz
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Jan C. Oosterwijk
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Harry J. de Koning
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Emiel J.T. Rutgers
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| | - Jan G.M. Klijn
- From the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam; Family Cancer Clinic, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Free University Medical Center, Amsterdam; Radboud University Medical Center and Hereditary Cancer Clinic, Nijmegen; Leiden University Medical Center, Leiden; and the Groningen University Medical Center, Groningen University, Groningen, the Netherlands
| |
Collapse
|
2
|
Stroom J, Schlief A, Alderliesten T, Peterse H, Bartelink H, Gilhuijs K. Using Histopathology Breast Cancer Data to Reduce Clinical Target Volume Margins at Radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74:898-905. [DOI: 10.1016/j.ijrobp.2009.01.026] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2008] [Revised: 12/17/2008] [Accepted: 01/21/2009] [Indexed: 10/20/2022]
|
3
|
Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2008; 9:R65. [PMID: 17910759 PMCID: PMC2242660 DOI: 10.1186/bcr1771] [Citation(s) in RCA: 428] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2007] [Revised: 09/11/2007] [Accepted: 10/02/2007] [Indexed: 02/06/2023] Open
Abstract
INTRODUCTION Breast cancer is a heterogeneous group of tumors, and can be subdivided on the basis of histopathological features, genetic alterations and gene-expression profiles. One well-defined subtype of breast cancer is characterized by a lack of HER2 gene amplification and estrogen and progesterone receptor expression ('triple-negative tumors'). We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases. METHODS 97 triple-negative tumors were selected from the fresh-frozen tissue bank of the Netherlands Cancer Institute, and gene-expression profiles were generated using 35K oligonucleotide microarrays. In addition, histopathological and immunohistochemical characterization was performed, and the findings were associated to clinical features. RESULTS All triple-negative tumors were classified as basal-like tumors on the basis of their overall gene-expression profile. Hierarchical cluster analysis revealed five distinct subgroups of triple-negative breast cancers. Multivariable analysis showed that a large amount of lymphocytic infiltrate (HR = 0.30, 95% CI 0.09-0.96) and absence of central fibrosis in the tumors (HR = 0.14, 95% CI 0.03-0.62) were associated with distant metastasis-free survival. CONCLUSION Triple-negative tumors are synonymous with basal-like tumors, and can be identified by immunohistochemistry. Based on gene-expression profiling, basal-like tumors are still heterogeneous and can be subdivided into at least five distinct subgroups. The development of distant metastasis in basal-like tumors is associated with the presence of central fibrosis and a small amount of lymphocytic infiltrate.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Adenoid Cystic/genetics
- Carcinoma, Adenoid Cystic/metabolism
- Carcinoma, Adenoid Cystic/pathology
- Carcinoma, Intraductal, Noninfiltrating/genetics
- Carcinoma, Intraductal, Noninfiltrating/metabolism
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/metabolism
- Carcinoma, Lobular/pathology
- ErbB Receptors/metabolism
- Gene Amplification
- Gene Expression Profiling
- Genes, erbB-2
- Humans
- Neoplasm Invasiveness
- Neoplasm Proteins/genetics
- Oligonucleotide Array Sequence Analysis
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
Collapse
Affiliation(s)
- Bas Kreike
- Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
- Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Marieke van Kouwenhove
- Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Hugo Horlings
- Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
- Division of Diagnostic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Britta Weigelt
- Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Hans Peterse
- Division of Diagnostic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Harry Bartelink
- Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Marc J van de Vijver
- Division of Diagnostic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| |
Collapse
|
4
|
Kriege M, Brekelmans CTM, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard APE, Tilanus-Linthorst MMA, Seynaeve C, Bartels CCM, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 2006; 102:357-63. [PMID: 17051427 DOI: 10.1007/s10549-006-9341-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2006] [Accepted: 07/12/2006] [Indexed: 01/21/2023]
Abstract
In the MRISC study, women with an inherited risk for breast cancer were screened by a 6-month clinical breast examination (CBE) and yearly MRI and mammography. We found that the MRISC screening scheme could facilitate early breast cancer diagnosis and that MRI was a more sensitive screening method than mammography, but less specific. In the current study we investigated the contribution of MRI in the early detection of breast cancer in relation to tumor characteristics. From November 1999 to October 2003, 1909 women were included and 50 breast cancers were detected, of which 45 were evaluable and included in the current study. We compared the characteristics of tumors detected by MRI-only with those of all other (non-palpable) screen-detected tumors. Further, we compared the sensitivity of mammography and MRI within subgroups according to different tumor characteristics. Twenty-two (49%) of the 45 breast cancers were detected by MRI and not visible at mammography, of which 20 (44%) were also not palpable (MRI-only detected tumors). MRI-only detected tumors were more often node-negative than other screen-detected cancers (94 vs. 59%; P=0.02) and tended to be more often <or=1 cm (58 vs. 31%; P=0.11). MRI was more sensitive than mammography for a wide spectrum of invasive tumor characteristics i.e., size, nodal status, histology, grade and ER status. Half of the breast cancers detected in this study were visible by MRI only and these tumors were smaller and significantly more often node-negative than other screen-detected tumors, suggesting that MRI makes an important contribution to the early detection of hereditary breast cancer.
Collapse
Affiliation(s)
- M Kriege
- Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC - Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ. Gene Expression Profiles of Primary Breast Carcinomas from Patients at High Risk for Local Recurrence after Breast-Conserving Therapy. Clin Cancer Res 2006; 12:5705-12. [PMID: 17020974 DOI: 10.1158/1078-0432.ccr-06-0805] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Several risk factors for local recurrence of breast cancer after breast-conserving therapy (BCT) have been identified. The identification of additional risk factors would be very useful in guiding optimal therapy and also in improving understanding of the mechanisms underlying local recurrence. We used cDNA microarray analysis to identify gene expression profiles associated with local recurrence. EXPERIMENTAL DESIGN Using 18K cDNA microarrays, gene expression profiles were obtained from 50 patients who underwent BCT. Of these 50 patients, 19 developed a local recurrence; the remaining 31 patients were selected as controls as they were free of local recurrence at least 11 years after treatment. For 9 of 19 patients, the local recurrence was also available for gene expression profiling. Unsupervised and supervised methods of classification were used to separate patients in groups corresponding to disease outcome and to study the overall gene expression pattern of primary tumors and their recurrences. RESULTS Hierarchical clustering of patients did not show any grouping reflecting local recurrence status. Supervised analysis revealed no significant set of genes that was able to distinguish recurring tumors from nonrecurring tumors. Paired-data analysis of primary tumors and local recurrences showed a remarkable similarity in gene expression profile between primary tumors and their recurrences. CONCLUSIONS No significant differences in gene expression between primary breast cancer tumors in patients with or without local recurrence after BCT were identified. Furthermore, analyses of primary tumors and local recurrences show a preservation of the overall gene expression pattern in the local recurrence, even after radiotherapy.
Collapse
MESH Headings
- Adult
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/metabolism
- Carcinoma, Lobular/surgery
- Female
- Gene Expression Profiling
- Humans
- Mastectomy, Segmental
- Middle Aged
- Neoplasm Recurrence, Local/diagnosis
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/metabolism
- Neoplasm Staging
- Oligonucleotide Array Sequence Analysis
- Prognosis
- Prospective Studies
- Risk Factors
Collapse
Affiliation(s)
- Bas Kreike
- Department of Radiation Oncology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
| | | | | | | | | | | | | |
Collapse
|
6
|
Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, Greco M, Houslton RS, Kuhl CK, Kurtz J, Palacios J, Peterse H, Rochard F, Rutgers E. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer 2006; 42:2205-11. [PMID: 16876991 DOI: 10.1016/j.ejca.2006.03.019] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2006] [Accepted: 03/21/2006] [Indexed: 11/22/2022]
Abstract
Lobular carcinoma in situ was first described over 60 years ago. Despite the long history, it continues to pose significant difficulties in screening, diagnosis, management and treatment. This is partly due its multi-focal and bilateral presentation, an incomplete understanding of its biology and natural history and perpetuation of misconceptions gathered over the last decades. In this review, the working group on behalf of EUSOMA has attempted to summarise the current thinking and management of this interesting lesion.
Collapse
Affiliation(s)
- Sunil R Lakhani
- Molecular and Cellular Pathology, School of Medicine, The University of Queensland, Mayne Medical School, Brisbane, QLD 4006, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Cserni G, Bianchi S, Vezzosi V, Peterse H, Sapino A, Arisio R, Reiner-Concin A, Regitnig P, Bellocq JP, Marin C, Bori R, Penuela JM, Iturriagagoitia AC. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518-22. [PMID: 16497870 PMCID: PMC1860289 DOI: 10.1136/jcp.2005.029991] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/10/2005] [Indexed: 11/04/2022]
Abstract
BACKGROUND Cytokeratin immunohistochemistry (IHC) reveals a higher rate of occult lymph node metastases among lobular carcinomas than among ductal breast cancers. IHC is widely used but is seldom recommended for the evaluation of sentinel lymph nodes in breast cancer patients. OBJECTIVE To assess the value of cytokeratin IHC for the detection of metastases in sentinel lymph nodes of patients with invasive lobular carcinoma. METHODS The value of IHC, the types of metastasis found by this method, and the involvement of non-sentinel lymph nodes were analysed in a multi-institutional cohort of 449 patients with lobular breast carcinoma, staged by sentinel lymph node biopsy and routine assessment of the sentinel lymph nodes by IHC when multilevel haematoxylin and eosin staining revealed no metastasis. RESULTS 189 patients (42%) had some type of sentinel node involvement, the frequency of this increasing with increasing tumour size. IHC was needed for identification of 65 of these cases: 17 of 19 isolated tumour cells, 40 of 64 micrometastases, and 8 of 106 larger metastases were detected by this means. Non-sentinel-node involvement was noted in 66 of 161 cases undergoing axillary dissection. Although isolated tumour cells were not associated with further lymph node involvement, sentinel node positivity detected by IHC was associated with further nodal metastases in 12 of 50 cases (0.24), a proportion that is higher than previously reported for breast cancer in general. CONCLUSIONS IHC is recommended for the evaluation of sentinel nodes from patients with lobular breast carcinoma, as the micrometastases or larger metastases demonstrated by this method are often associated with a further metastatic nodal load.
Collapse
Affiliation(s)
- G Cserni
- Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kriege M, Brekelmans C, Boetes C, Peterse H, Tollenaar R, Oosterwijk J, Manoliu R, de Koning H, Rutgers E, Klijn J. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80070-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
9
|
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72. [PMID: 16478745 DOI: 10.1093/jnci/djj052] [Citation(s) in RCA: 1461] [Impact Index Per Article: 81.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Histologic grade in breast cancer provides clinically important prognostic information. However, 30%-60% of tumors are classified as histologic grade 2. This grade is associated with an intermediate risk of recurrence and is thus not informative for clinical decision making. We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading. METHODS We analyzed microarray data from 189 invasive breast carcinomas and from three published gene expression datasets from breast carcinomas. We identified differentially expressed genes in a training set of 64 estrogen receptor (ER)-positive tumor samples by comparing expression profiles between histologic grade 3 tumors and histologic grade 1 tumors and used the expression of these genes to define the gene expression grade index. Data from 597 independent tumors were used to evaluate the association between relapse-free survival and the gene expression grade index in a Kaplan-Meier analysis. All statistical tests were two-sided. RESULTS We identified 97 genes in our training set that were associated with histologic grade; most of these genes were involved in cell cycle regulation and proliferation. In validation datasets, the gene expression grade index was strongly associated with histologic grade 1 and 3 status; however, among histologic grade 2 tumors, the index spanned the values for histologic grade 1-3 tumors. Among patients with histologic grade 2 tumors, a high gene expression grade index was associated with a higher risk of recurrence than a low gene expression grade index (hazard ratio = 3.61, 95% confidence interval = 2.25 to 5.78; P < .001, log-rank test). CONCLUSIONS Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence. This approach may improve the accuracy of tumor grading and thus its prognostic value.
Collapse
Affiliation(s)
- Christos Sotiriou
- Functional Genomics and Translational Research Unit, Université Libre de Bruxelles, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MMA, Muller SH, Meijer S, Oosterwijk JC, Beex LVAM, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427-37. [PMID: 15282350 DOI: 10.1056/nejmoa031759] [Citation(s) in RCA: 1100] [Impact Index Per Article: 55.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women. METHODS Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups. RESULTS We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity of clinical breast examination, mammography, and MRI for detecting invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively, and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The overall discriminating capacity of MRI was significantly better than that of mammography (P<0.05). The proportion of invasive tumors that were 10 mm or less in diameter was significantly greater in our surveillance group (43.2 percent) than in either control group (14.0 percent [P<0.001] and 12.5 percent [P=0.04], respectively). The combined incidence of positive axillary nodes and micrometastases in invasive cancers in our study was 21.4 percent, as compared with 52.4 percent (P<0.001) and 56.4 percent (P=0.001) in the two control groups. CONCLUSIONS MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer.
Collapse
Affiliation(s)
- Mieke Kriege
- Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bosma A, Weigelt B, Verduijn P, Rutgers E, Peterse H, van 't Veer L. Discovery of previously undetected micrometastases by mRNA markers in sentinel lymph nodes of breast cancer patients. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90685-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Kriege M, Brekelmans C, Boetes C, Rutgers E, Tollenaar R, Oosterwijk J, Manoliu R, Peterse H, de Koning H, Klijn J. Prevalent and incident rounds in a breast cancer screening program with mammography and MRI for high risk women. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90710-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
13
|
Van de Vijver MJ, Peterse H. The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications. Breast Cancer Res 2003; 5:269. [PMID: 12927038 PMCID: PMC314433 DOI: 10.1186/bcr629] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
In this review, we comment on the reasons for disagreement in the concepts, diagnosis and classifications of pre-invasive intraductal proliferations. In view of these disagreements, our proposal is to distinguish epithelial hyperplasia, lobular carcinoma in situ and ductal carcinoma in situ, and to abandon the use of poorly reproducible categories, such as atypical ductal hyperplasia or ductal intraepithelial neoplasia, followed by a number to indicate the degree of proliferation and atypia, as these are not practical for clinical decision making, nor for studies aimed at improving the understanding of breast cancer development. If there is doubt about the classification of an intraductal proliferation, a differential diagnosis and the reason for and degree of uncertainty should be given, rather than categorizing a proliferation as atypical.
Collapse
|
14
|
Taal BG, Boot H, Peterse H. Gastrointestinal metastases in lobular breast cancer. Ann Oncol 2001; 12:1765. [PMID: 11843257 DOI: 10.1023/a:1013557304793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29:418-25. [PMID: 11694875 DOI: 10.1038/ng747] [Citation(s) in RCA: 816] [Impact Index Per Article: 35.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Inheritance of one defective BRCA2 allele predisposes humans to breast cancer. To establish a mouse model for BRCA2-associated breast cancer, we generated mouse conditional mutants with BRCA2 and/or p53 inactivated in various epithelial tissues, including mammary-gland epithelium. Although no tumors arose in mice carrying conditional Brca2 alleles, mammary and skin tumors developed frequently in females carrying conditional Brca2 and Trp53 alleles. The presence of one wildtype Brca2 allele resulted in a markedly delayed tumor formation; loss of the wildtype Brca2 allele occurred in a subset of these tumors. Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer.
Collapse
Affiliation(s)
- J Jonkers
- Division of Molecular Genetics and Centre of Biomedical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
16
|
Abstract
BACKGROUND Breast carcinoma is the most common malignancy in women. Metastatic involvement of the stomach is not well known. METHODS Endoscopic features and treatment options were evaluated retrospectively for 51 patients with gastric metastases of breast carcinoma. RESULTS The presenting sites of metastases were skeleton (43%), stomach (27%), lung (8%), and liver (4%). Diagnosis of gastric involvement was histologically confirmed in 41 patients and based on endoscopic features, despite negative biopsies in 10 patients. Six patients (12%) presented with nonfatal hemorrhage; in the others, symptoms were nonspecific: anorexia (71%), epigastric pain (53%), and vomiting (41%). Endoscopy showed 3 patterns: 18% localized lesions, 57% diffuse infiltration, and 25% external compression at the cardia or pylorus. Histology showed mainly lobular breast carcinoma (n = 36) compared with ductal carcinoma (n = 10) and other types (n = 5), contrary to the usual distribution. The overall response to systemic therapy was 46% (17 of 37 treated patients). Median survival from detection of gastric metastases was 10 months, with a 2-year survival rate of 23%. CONCLUSIONS Gastric metastases usually derive from lobular rather than ductal breast carcinoma. Endoscopy revealed mainly a diffuse linitis plastica-like infiltration. Chemotherapy or hormonal treatment may result in fair palliation in selected patients, although many patients are heavily pretreated.
Collapse
Affiliation(s)
- B G Taal
- Department of Gastroenterology, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam.
| | | | | |
Collapse
|
17
|
Abstract
BACKGROUND Breast carcinoma is the most common malignancy in women. Metastatic involvement of the stomach is not well known. METHODS Endoscopic features and treatment options were evaluated retrospectively for 51 patients with gastric metastases of breast carcinoma. RESULTS The presenting sites of metastases were skeleton (43%), stomach (27%), lung (8%), and liver (4%). Diagnosis of gastric involvement was histologically confirmed in 41 patients and based on endoscopic features, despite negative biopsies in 10 patients. Six patients (12%) presented with nonfatal hemorrhage; in the others, symptoms were nonspecific: anorexia (71%), epigastric pain (53%), and vomiting (41%). Endoscopy showed 3 patterns: 18% localized lesions, 57% diffuse infiltration, and 25% external compression at the cardia or pylorus. Histology showed mainly lobular breast carcinoma (n = 36) compared with ductal carcinoma (n = 10) and other types (n = 5), contrary to the usual distribution. The overall response to systemic therapy was 46% (17 of 37 treated patients). Median survival from detection of gastric metastases was 10 months, with a 2-year survival rate of 23%. CONCLUSIONS Gastric metastases usually derive from lobular rather than ductal breast carcinoma. Endoscopy revealed mainly a diffuse linitis plastica-like infiltration. Chemotherapy or hormonal treatment may result in fair palliation in selected patients, although many patients are heavily pretreated.
Collapse
Affiliation(s)
- B G Taal
- Department of Gastroenterology, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam.
| | | | | |
Collapse
|
18
|
Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000. [PMID: 10861499 DOI: 10.1002/1097-0215(20000520)89:3<236::aid-ijc5>3.0.co;2-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
p27(Kip1) (p27), a cyclin-dependent kinase inhibitor, has an important role in the progression of cells from G(1) into S phase of the cell cycle. p27 may act as a tumor suppressor, and several reports suggest that loss of its expression in breast carcinoma is related to tumor progression and poor prognosis. We evaluated p27 immunohistochemical expression in 512 consecutive cases of breast carcinoma with 9 years of median-term follow-up. p27 expression was heterogeneous and frequently less intense than in normal cells. Low p27 expression (<50% of reacting cells) was associated with grade III tumors, N0 status, estrogen receptor-negative status, and low cyclin D1 expression. In the whole series of cases, p27 expression did not predict outcome. In node-negative cases (249 patients), high p27 expression indicated poor prognosis. p27 was not prognostically relevant in the group of 223 patients with pT1 disease or in the group of 154 patients <50 years of age. We also investigated the prognostic value of the combined expression of p27 and cyclin D1, but no differences in survival were seen in this bivariate analysis.
Collapse
Affiliation(s)
- M Barbareschi
- Department of Histopathology, St. Chiara Hospital, Trento, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Robanus-Maandag E, Bosch C, Vos C, Peterse H, van de Vijver M. Genetic alterations in ductal carcinoma in situ and invasive carcinoma of the breast. Breast Cancer Res 2000. [PMCID: PMC3300823 DOI: 10.1186/bcr124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
20
|
Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R. p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000. [DOI: 10.1002/1097-0215(20000520)89:3<236::aid-ijc5>3.0.co;2-z] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
21
|
|
22
|
Taal BG, Cohen P, Peterse H, Boot H, Tytgat GN. Recurrent esophagorespiratory fistula in a patient with metastatic breast cancer: long-term palliation with endoprostheses and hormonal therapy. Gastrointest Endosc 1995; 42:84-8. [PMID: 7557187 DOI: 10.1016/s0016-5107(95)70252-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- B G Taal
- Department of Gastroenterology, Radiology and Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoekziekenhuis, Amsterdam
| | | | | | | | | |
Collapse
|
23
|
Abstract
A series of eight patients with chronic lymphedema-related lymphangiosarcoma is presented. All but one case showed a typical rapid progression and fatal outcome, as has been reported in other series. In one patient the lymphangiosarcoma developed on the chest wall, the axilla and the arm where persisting lymphedema and fibrosis occurred after bilateral mastectomy and bilateral postoperative radiotherapy. In this patient an asymptomatic course and slow locoregional progression of lesions was seen. The clinical picture, the etiological considerations and the therapeutic options of the lymphedema-induced lymphangiosarcoma with regard to the literature are discussed.
Collapse
Affiliation(s)
- A J Janse
- Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek ziekenhuis, Amsterdam
| | | | | | | | | |
Collapse
|
24
|
Kemperman H, Borger J, Hart A, Peterse H, Bartelink H, van Dongen J. Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer. The role of local recurrence. Eur J Cancer 1995; 31A:690-8. [PMID: 7640040 DOI: 10.1016/0959-8049(94)00526-b] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Risk factors for local recurrence (LR) in a univariate analysis had a significant correlation with survival. Local and distant failure could not be regarded as independent events. We undertook a multivariate survival analysis to study the relation between LR and survival. In a retrospective study of 1026 patients treated with tumorectomy, axillary dissection and radiotherapy, factors associated with disease-specific survival (DSS) were analysed. Actuarial estimates for DSS are 91% at 5 years and 86% at 10 years. The multivariate analysis revealed five factors: clinical stage, number of affected axillary nodes, histological grade, degree of tubule formation and left-sided primary tumour. Controlling for these factors, LR appeared to be significantly correlated with DSS. The hazard rate of DSS was estimated to increase by a factor 8.8 (95% confidence interval 4.6-16.8) upon occurrence of a LR. Local recurrence per se, apart from the identified prognostic factors, is a risk factor for DSS. The exact mechanism by which LR has an influence on survival cannot be clarified from these data.
Collapse
Affiliation(s)
- H Kemperman
- Dept. of Surgery, Nederlands Kanker Instituut/Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
PURPOSE To identify clinical and pathologic factors associated with an increased risk of local recurrence following breast-conservation therapy (BCT) to assess the safety of this procedure for all subgroups of patients. PATIENTS AND METHODS The study population consisted of 1,026 patients with clinical stage I and II breast cancer treated between 1979 and 1988 at the Netherlands Cancer Institute. The BCT regimen consisted of local excision and axillary lymph node dissection (ALND) followed by whole-breast irradiation to a total dose of 50 Gy in 2-Gy fractions and boost irradiation (mostly by iridium implant) of 15 to 25 Gy. RESULTS With a median follow-up duration of 66 months, the actuarial breast recurrence rate was 4% at 5 years, counting all breast recurrences. Univariate analysis showed seven factors to be associated with an increased risk of local recurrence; age, residual tumor at reexcision, histologic tumor type, presence of any carcinoma-in-situ component, vascular invasion, microscopic margin involvement, and whole-breast radiation dose. Three factors remained independently significant after proportional hazard regression analysis: age, margin involvement, and the presence of vascular invasion. When the analysis was repeated, but counting only those breast recurrences that occurred before regional or distant failures, only young age and vascular invasion were independent predictive factors. In the third analysis, factors predicting the necessity of local salvage treatment were analyzed. In this analysis, the possible bias in the former analysis caused by censoring actuarial methods was avoided. The results were the same as in the second analysis, showing young age and vascular invasion as the only independent predictive factors. Breast recurrence rates were 6% for patients less than 40 years of age and 8% for patients with tumors showing vascular invasion. In the absence of risk factors, the breast recurrence rate is only 1% at 5 years. CONCLUSION Slightly higher recurrence rates were found in patients less than 40 years of age and in patients with tumors showing vascular invasion. The role of margin involvement is uncertain.
Collapse
Affiliation(s)
- J Borger
- Department of Radiotherapy, Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
In a 15-year period at the Netherlands Cancer Institute, 17 patients were found with breast carcinoma metastatic to the colon or rectum or both. The presenting symptoms and signs were non-specific and included diarrhea, crampy pain, vomiting, and palpable tumor. Endoscopic examination, possible in only 10 of the 17 patients because of luminal obstruction, yielded a correct diagnosis in seven cases. Biopsy was confirmatory in five cases. Lesions metastatic to the colorectum originated predominantly in lobular carcinoma of the breast. Systemic hormonal or chemotherapy or x-irradiation, either alone or as an adjunct to surgery, produced a favorable response in over half the patients so treated.
Collapse
Affiliation(s)
- B G Taal
- Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam
| | | | | | | |
Collapse
|
27
|
Abstract
In a 15-year period at the Netherlands Cancer Institute, 27 patients were found with breast carcinoma metastatic to the stomach. Presenting symptoms were non-specific, mainly nausea, vomiting, dysphagia, epigastric pain, and melena. Endoscopy, performed in 22 of these patients, yielded a correct diagnosis in 13. Lobular rather than ductal breast carcinoma was the predominant source of gastric metastases in this series. Non-surgical treatment was rewarded by a favorable, palliative response in 32% of cases.
Collapse
Affiliation(s)
- B G Taal
- Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam
| | | | | | | |
Collapse
|
28
|
Uyterlinde AM, Baak JP, Schipper NW, Peterse H, Matze E, Meijer CJ. Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer patients with long follow-up. Int J Cancer 1990; 45:1-7. [PMID: 2298493 DOI: 10.1002/ijc.2910450102] [Citation(s) in RCA: 66] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The added prognostic value of cellular DNA content compared with single and combined morphometric factors and classical parameters such as tumor size, nodal status, histologic grade and estrogen receptor (ER) content was investigated in 225 consecutive breast-cancer patients with long follow-up. Of all features investigated, the MPI (multivariate prognostic index) had the strongest prognostic value [Mantel-Cox (MC) = 48.2, p less than 0.00005]. The results further showed that neither age nor ER content had significant prognostic value, but the DNA index (DI) as a single parameter had (though weak) prognostic significance (MC = 5.9, p = 0.015); a similar result was obtained with the percentage of S-phase cells (MC = 6.1, p = 0.013). The DI had (restricted) additional prognostic value to the morphometric features (MPI plus DI Mantel-Cox 53.0, p less than 0.0001). The percentage of S-phase cells had no additional prognostic value over the MPI. On the other hand, the additional value of the DI over tumor size and nodal status was much more impressive (MC = 41.0 and 40.7), although it did not reach the prognostic significance of the MPI. Prediction of disease outcome with a linear combination of quantitative microscopical parameters of the primary tumor alone [MAI (mitotic activity index), DI and mean nuclear area] was very accurate, even without considering lymph-node status (MC 30.8, p less than 0.0005). Grade had no additional value to the MPI at all (p = 0.76). This could be especially important for lymph-node-negative patients in whom the prognostic value of the MPI and the MAI are confirmed.
Collapse
Affiliation(s)
- A M Uyterlinde
- Free University Hospital, Department of Pathology, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
29
|
Uyterlinde AM, Schipper NW, Baak JP, Peterse H, Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol 1988; 89:301-7. [PMID: 2831704 DOI: 10.1093/ajcp/89.3.301] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
This retrospective study evaluates several prognostic factors in 63 patients with invasive ductal breast cancer. Special attention is paid to the additional prognostic value of cellular DNA content to the previously developed and evaluated quantitative features mitotic activity index (MAI) and multivariate morphometric prognostic index (MPI). Follow-up was monitored for at least 50 months (median survival, 78 months) and only patients who died of distant metastases were included. The results show that the MAI is the strongest prognostic factor of all single features (Mantel-Cox, P = 0.008). Although patients with a diploid or tetraploid tumor tended to have a better prognosis than those with an aneuploid cancer, the DNA index as a single parameter was a weak prognosticator in the univariate survival analysis (Mantel-Cox, P = 0.24). Within the diploid and tetraploid tumors the MAI could distinguish patients with a favorable and unfavorable prognosis prediction (chi-square, P = 0.01). For aneuploid tumors this was not possible. Analysis of combined features revealed that the MPI has a high prognostic value (Mantel-Cox, P = 0.0015), thus confirming other studies. A linear combination of the nuclear DNA index, MAI, nodal status, and mean nuclear area showed only a slight improvement in prognosis prediction compared with the MPI (Mantel-Cox, P = 0.0005); with this rule, the classification of the patients was more in agreement with the actual outcome in 4% of the cases. The gain was in the poor prognosis group. These results suggest that the additional prognostic value of nuclear DNA content is restricted when compared with the morphometric prognostic factors. Further studies on a larger number of patients are required to confirm these findings.
Collapse
Affiliation(s)
- A M Uyterlinde
- Pathological Institute, Free University Hospital, The Netherlands
| | | | | | | | | |
Collapse
|